Literature DB >> 14749034

Increased hypocretin-1 (orexin-a) levels in cerebrospinal fluid of rats after short-term forced activity.

Paulo J F Martins1, Vânia D'Almeida, Mário Pedrazzoli, Ling Lin, Emmanuel Mignot, Sergio Tufik.   

Abstract

The hypocretins (orexins) are recently discovered neuropeptides initially associated with feeding behavior and sleep regulation. However, the normal function of these peptides is unclear and a number of studies have reported a role in energy homeostasis and locomotor activity. Exercise (or physical activity) is the most powerful way of challenging the internal homeostatic process. This study examines the circadian differences in response to forced activity and homeostatic challenges on hypocretin-1 (Hcrt-1) levels in the cerebrospinal fluid (CSF) of rats. Hcrt-1 levels were decreased after long-term immobilization at the end of active phase (zeigeber time-0, ZT-0) and increased after short-term forced swimming in the rest phase (ZT-8). Nevertheless, no effects were observed after short-term immobilization, total sleep deprivation or cold exposure. We concluded that despite the relation between hypocretins, stress and sleep regulation reported in the literature, short-term total sleep deprivation, immobilization and cold exposure did not induce increases in CSF Hcrt-1 levels at ZT-0 and ZT-8. On the other hand, the relationship between hypocretinergic system activation and motor activation is reinforced by decrease in Hcr-1 levels after long-term immobilization at ZT-0 and its increased levels after short-term forced swimming at ZT-8 in CSF of rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749034     DOI: 10.1016/j.regpep.2003.10.003

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  32 in total

Review 1.  State-dependent central chemoreception: a role of orexin.

Authors:  Tomoyuki Kuwaki; Aihua Li; Eugene Nattie
Journal:  Respir Physiol Neurobiol       Date:  2010-02-17       Impact factor: 1.931

Review 2.  Waking with the hypothalamus.

Authors:  Helmut L Haas; Jian-Sheng Lin
Journal:  Pflugers Arch       Date:  2011-07-28       Impact factor: 3.657

Review 3.  A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?

Authors:  Morgan H James; Stephen V Mahler; David E Moorman; Gary Aston-Jones
Journal:  Curr Top Behav Neurosci       Date:  2017

Review 4.  Orexin, stress, and anxiety/panic states.

Authors:  Philip L Johnson; Andrei Molosh; Stephanie D Fitz; William A Truitt; Anantha Shekhar
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 5.  Respiration and autonomic regulation and orexin.

Authors:  Eugene Nattie; Aihua Li
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

6.  MCH-containing neurons in the hypothalamus of the cat: searching for a role in the control of sleep and wakefulness.

Authors:  Pablo Torterolo; Sharon Sampogna; Francisco R Morales; Michael H Chase
Journal:  Brain Res       Date:  2006-10-09       Impact factor: 3.252

Review 7.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

8.  The effect of clomipramine on wake/sleep and orexinergic expression in rats.

Authors:  P Feng; Y Hu; D Li; D Vurbic; H Fan; S Wang; K P Strohl
Journal:  J Psychopharmacol       Date:  2008-06-18       Impact factor: 4.153

9.  Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models.

Authors:  Christelle Anaclet; Régis Parmentier; Koliane Ouk; Gérard Guidon; Colette Buda; Jean-Pierre Sastre; Hidéo Akaoka; Olga A Sergeeva; Masashi Yanagisawa; Hiroshi Ohtsu; Patricia Franco; Helmut L Haas; Jian-Sheng Lin
Journal:  J Neurosci       Date:  2009-11-18       Impact factor: 6.167

10.  Hypocretin/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis.

Authors:  A Nuñez; M L Rodrigo-Angulo; I De Andrés; M Garzón
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.